• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by IMAC Holdings Inc.

    2/19/25 4:58:30 PM ET
    $BACK
    Medical Specialities
    Health Care
    Get the next $BACK alert in real time by email
    424B5 1 form424b5.htm

     

    Filed pursuant to Rule 424(b)(5)

    Registration No. 333-280184

     

    PROSPECTUS SUPPLEMENT

    Supplement No. 1 to Prospectus dated February 14, 2025

     

     

    Up to 35,007,025 Shares of Common Stock

     

    This supplement no. 1 dated February 19, 2025, or the Prospectus Supplement, supplements, modifies and supersedes, only to the extent indicated herein, certain information contained in our prospectus dated February 14, 2025, or the Prospectus, as a part of our registration statement on Form S-1 (File No. 333-280184) (the “Registration Statement”), relating to the potential resale from time to time by Keystone Capital Partners, LLC, or Keystone or the Selling Stockholder, of up to 35,007,025 shares of common stock, par value $0.001 per share, or common stock. The shares of common stock to which this prospectus relates consist of shares that have been or may be issued by us to the Selling Stockholder pursuant to a Common Stock Purchase Agreement, dated as of November 12, 2024, by and between us and the Selling Stockholder, or the Purchase Agreement, establishing an equity line of credit, or the Equity Financing. Such shares of our common stock include (i) 164,000 shares of common stock, or the Initial Commitment Shares, issuable to Keystone under the Purchase Agreement on the date on which the registration statement of which this prospectus is apart is declared effective by the Securities and Exchange Commission, or the SEC, and (ii) $1 million of shares of common stock (1,666,667 shares of common stock assuming a price per share of $0.60), or the Back-End Commitment Shares (and together with the Initial Commitment Shares, the Commitment Shares), issuable to Keystone under the Purchase Agreement on the trading day following stockholder approval of our issuance of more than 402,438 shares of common stock to Keystone at an average per share price lower than the Minimum Price (as defined below) and (iii) up to $60 million of shares of common stock (or up to the 33,176,358 shares of common stock remaining of the common stock registered for resale pursuant to this prospectus after issuance of the Commitment Shares), or the Purchase Shares, that we may elect, in our sole discretion, to issue and sell to Keystone, from time to time from after the date the registration statement that includes this prospectus is declared effective by the SEC and after satisfaction of other conditions in the Purchase Agreement, or the Commencement Date, and subject to applicable stock exchange rules. This supplement should be read in conjunction with, is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including all supplements thereto and documents incorporated by reference therein. If there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on the information in this Prospectus Supplement. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this supplement.

     

     

     

     

    SELLING STOCKHOLDER

     

    This prospectus relates to the possible resale from time to time by Keystone of any or all of the shares of common stock that may be issued by us to Keystone under the Purchase Agreement. For additional information regarding the issuance of common stock covered by this prospectus, see the section titled “Committed Equity Financing” above. We are registering 35,007,025 shares of common stock pursuant to the provisions of the Registration Rights Agreement in order to permit the selling stockholder to offer the shares for resale from time to time. Except for the transactions contemplated by the Purchase Agreement and the Registration Rights Agreement, the purchase by Keystone of September-October Notes in the principal amount of $630,000, for an aggregate purchase price of $450,000 all of which were repaid on November 14, 2024 and the purchase on November 14, 2024 by Keystone of 1,101 shares of our Series G Preferred Stock for an aggregate purchase price of $880,000, Keystone Capital has not had any material relationship with us within the past three years.

     

    The table below presents information regarding the Selling Stockholder and the shares of common stock that it may offer from time to time under this prospectus. This table is prepared based on information supplied to us by the selling stockholder, and reflects holdings as of February 5, 2025. The number of shares in the column “Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus” represents all of the shares of common stock that the Selling Stockholder may offer under this prospectus. The Selling Stockholder may sell some, all or none of its shares in this offering. We do not know how long the Selling Stockholder will hold the shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholder regarding the sale of any of the shares.

     

    Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of common stock with respect to which the selling stockholder has voting and investment power. The percentage of shares of common stock beneficially owned by the selling stockholder prior to the offering shown in the table below is based on an aggregate of 3,365,866 shares of our common stock outstanding on February 5, 2025. Because the purchase price of the common stock issuable under the Purchase Agreement is determined on each Fixed Purchase Date, with respect to a Fixed Purchase, on the applicable VWAP Purchase Date, with respect to a VWAP Purchase, and on the applicable Additional VWAP Purchase Date, with respect to an Additional VWAP Purchase, the number of shares that may actually be sold by the Company to the Keystone Capital Partners under the Purchase Agreement may be fewer than the number of shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the selling stockholder pursuant to this prospectus.

     

    Name of Selling Stockholder 

    Number of Shares of

    Common Stock Owned

    Prior to Offering

       Maximum Number of Shares of Common Stock to be Offered Pursuant to this Prospectus  

    Number of Shares of

    Common Stock Owned

    After Offering

     
       Number(1)   Percent(2)       Number(3)   Percent(2) 
    Keystone Capital Partners, LLC(4)   874,625    4.99%   35,007,025    710,625    * 

     

     

    * Represents beneficial ownership of less than 1% of our outstanding common stock.

     

      (1) This number includes (i) the 164,000 shares of common stock we have issued, or will issue, to Keystone as the Initial Commitment Shares in consideration for entering into the Purchase Agreement with us upon effectiveness of the Registration Statement and (ii) 710,625 shares of common stock issuable upon conversion of 1,101 shares of currently convertible Series G Preferred Stock held by Keystone. In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that Keystone Capital may be required to purchase under the Purchase Agreement, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction of which are entirely outside of Keystone’s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the Fixed Purchases, VWAP Purchase, or Additional VWAP Purchase, as applicable, of common stock are subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement.
         
      (2) Applicable percentage ownership is based on 3,365,866 shares of our common stock outstanding as of February 5, 2025 plus the shares of common stock to be issued upon conversion of shares of our Series G Preferred Stock held by Keystone and the Initial Commitment Shares. However, the Purchase Agreement prohibits us from issuing and selling any shares of our common stock to Keystone to the extent such shares, when aggregated with all other shares of our common stock then beneficially owned by Keystone, would cause Keystone Capital’s beneficial ownership of our common stock to exceed the 4.99% of our then outstanding common stock.
         
      (3) Assumes the sale of all shares being offered pursuant to this prospectus.
         
      (4) The business address of Keystone Capital Partners, LLC is 139 Fulton Street, Suite 412, New York, NY 10038. Keystone Capital Partners, LLC’s principal business is that of a private investor. Ranz Group, LLC, a Delaware limited liability company, is the managing member of Keystone Capital Partners, LLC and the beneficial owner of 97% of the membership interests in Keystone Capital Partners, LLC. Fredric G. Zaino is the managing member of Ranz Group, LLC and has sole voting control and investment discretion over securities beneficially owned directly by Keystone Capital, LLC and indirectly by Ranz Group, LLC. We have been advised that none of Mr. Zaino, Ranz Group, LLC or Keystone Capital Partners, LLC is a member of the Financial Industry Regulatory Authority, or FINRA, or an independent broker-dealer, or an affiliate or associated person of a FINRA member or independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Mr. Zaino as to beneficial ownership of the securities beneficially owned directly by Keystone Capital Partners, LLC and indirectly by Ranz Group, LLC.

     

     

     

    Get the next $BACK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BACK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 12:01:15 PM ET
    $BACK
    Medical Specialities
    Health Care

    Large owner Ruiz Jorge bought $590,192 worth of shares (164,872 units at $3.58) and sold $39,955 worth of shares (16,487 units at $2.42) (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/14/25 3:43:49 PM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers

    The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB:BACK), today announced that it has entered into a research collaboration with Inova Health to apply Ignite's Reverse Phase Protein Array (RPPA) technology to tumor samples from patients, primarily with late-stage gastrointestinal cancers. The data provided from the analysis by RPPA will be used to help oncologists select from multiple treatment options where no current guidance is available. Under the agreement, Ignite will analyze up

    9/10/25 3:04:30 PM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings Announces Research Collaboration with Vanderbilt University Medical Center to Advance Immuno-Oncology Biomarker Discovery

    Project will leverage Ignite Proteomics' reverse-phase protein array (RPPA) platform to profile tumor-immune signaling in breast-cancer samples Golden, CO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (OTCQB:BACK), today announced a one-year research collaboration with Vanderbilt University Medical Center (VUMC) to characterize protein-signaling pathways that help breast-tumor cells evade the immune system. Under the agreement, VUMC will provide de-identified formalin-fixed, paraffin-embedded (FFPE) tumor tissue from patients undergoing standard of care chemotherapy and immunotherapy, while Ignite will perform laser-capture micro-dissection

    8/7/25 4:05:00 PM ET
    $BACK
    Medical Specialities
    Health Care

    Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

    Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda®) compared to PD-L1 at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference. The study, conducted with I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies – including the one most commonly used as a companion diagnostic – yet only MHC-II expression showed a statistically significant correlation with patient outcomes. "Although PD-L1 testing is standard in some cases, many pati

    2/24/25 8:15:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    SEC Filings

    View All

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    1/30/26 4:37:13 PM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    1/16/26 4:00:26 PM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    12/30/25 5:02:04 PM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Ruiz Jorge

    5 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 12:03:25 PM ET
    $BACK
    Medical Specialities
    Health Care

    Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 12:01:15 PM ET
    $BACK
    Medical Specialities
    Health Care

    Large owner Ruiz Jorge sold $15,000 worth of shares (5,000 units at $3.00), decreasing direct ownership by 3% to 141,229 units (SEC Form 4)

    4 - IMAC Holdings, Inc. (0001729944) (Issuer)

    3/18/25 11:59:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Financials

    Live finance-specific insights

    View All

    IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

    FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ:BACK) ("BACK") and Theralink Technologies, Inc. ("Theralink"), BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK's agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink's business. With BACK already in possession of such assets of Theralink,

    5/7/24 8:30:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market

    Franklin, Tennessee, July 26, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments, announced today that it entered into a definitive securities purchase agreement with several institutional and accredited investors, including existing significant investors of Theralink Technologies, Inc., its previously announced merger partner (OTC:THER) ("Theralink"), and Theralink's Chairman, for the sale of its preferred stock and warrants. IMAC sold an aggregate of 2,500 shares of its Series A-1 Convertible Preferred Stock, stated value $1,000 per s

    7/26/23 9:25:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    IMAC Holdings, Inc announces the sale of The BackSpace

    BRENTWOOD, Tenn., March 01, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC" or the "Company"), announces today it has completed the sale of The BackSpace for an undisclosed price to Curis Functional Health. The BackSpace offers convenient and affordable spinal health and wellness services in select Walmart locations. "We are excited for the Curis team to support and grow the business going forward while we return our focus to non-surgical medical care for a person's optimal orthopedic function, stability, and mobility," said Jeff Ervin, Chief Executive Officer of IMAC. In addition to the sale of The BackSpace, the Company's Chief Operating Officer, Dr. Ben Lerner, ann

    3/1/23 9:30:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Leadership Updates

    Live Leadership Updates

    View All

    IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

    Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) (the "Company" or "IMAC"), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move underscores the Company's commitment to advancing its position in the field of proteomics and driving innovation in precision medicine. Dr. Matthew Schwartz brings over 18 years of experience in the care of cancer patients using radiotherapy treatments and precision oncology. He currently serves as a practicing Radiation Oncologist at Comprehensive Cancer Centers of Nevada. "I am hono

    7/11/24 9:21:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    DayDayCook Names Jeffrey Ervin as Co-Chief Financial Officer

    NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- DDC Enterprise, Ltd., (NYSEAM:DDC) ("DayDayCook," "DDC," or the "Company"), a leading content-driven food consumer brand, today announced that Jeffrey Ervin, has been named Co-Chief Financial Officer, effective immediately. Mr. Ervin will initially be focused on leveraging his background in U.S. capital markets to oversee the financial controls, reporting requirements, and aid in investor engagement for DayDayCook. "Jeff's background as a public company CEO, along with his extensive experience in corporate finance, will be instrumental in establishing DayDayCook in the U.S. financial markets" said Norma Chu, DayDayCook's founder and CEO. "With o

    6/25/24 9:00:00 AM ET
    $BACK
    $DDC
    Medical Specialities
    Health Care
    Packaged Foods
    Consumer Staples

    IMAC Holdings Announces Leadership Succession

    Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC") today announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed chief executive officer, succeeding Jeff Ervin, to lead newly acquired assets in the proteomics and precision medicine industry. "I am excited and honored to join IMAC and continue the mission that Jeff and team created, which is focused on providing better outcomes for patients," said Ms. Zaslavsky. "In the 23 years of working in the genomic space, I have never been more excited about a product and the brilliant and dynami

    5/24/24 9:00:00 AM ET
    $BACK
    Medical Specialities
    Health Care

    $BACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by IMAC Holdings Inc. (Amendment)

    SC 13G/A - IMAC Holdings, Inc. (0001729944) (Subject)

    2/7/23 2:03:35 PM ET
    $BACK
    Medical Specialities
    Health Care